Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.87 (-1.41%)
AAPL   144.52 (-2.42%)
MSFT   241.12 (-2.57%)
META   108.74 (-2.40%)
GOOGL   96.12 (-1.37%)
AMZN   94.11 (+0.75%)
TSLA   182.92 (+0.03%)
NVDA   158.20 (-2.77%)
NIO   10.12 (-0.49%)
BABA   75.80 (+0.40%)
AMD   73.12 (-2.69%)
T   18.79 (-1.73%)
MU   55.74 (-4.57%)
CGC   3.41 (-6.83%)
F   13.73 (-2.49%)
GE   85.49 (-3.01%)
DIS   95.70 (-3.21%)
AMC   7.36 (-2.00%)
PYPL   79.88 (-0.25%)
PFE   49.58 (+0.75%)
NFLX   281.33 (-1.47%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.87 (-1.41%)
AAPL   144.52 (-2.42%)
MSFT   241.12 (-2.57%)
META   108.74 (-2.40%)
GOOGL   96.12 (-1.37%)
AMZN   94.11 (+0.75%)
TSLA   182.92 (+0.03%)
NVDA   158.20 (-2.77%)
NIO   10.12 (-0.49%)
BABA   75.80 (+0.40%)
AMD   73.12 (-2.69%)
T   18.79 (-1.73%)
MU   55.74 (-4.57%)
CGC   3.41 (-6.83%)
F   13.73 (-2.49%)
GE   85.49 (-3.01%)
DIS   95.70 (-3.21%)
AMC   7.36 (-2.00%)
PYPL   79.88 (-0.25%)
PFE   49.58 (+0.75%)
NFLX   281.33 (-1.47%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.87 (-1.41%)
AAPL   144.52 (-2.42%)
MSFT   241.12 (-2.57%)
META   108.74 (-2.40%)
GOOGL   96.12 (-1.37%)
AMZN   94.11 (+0.75%)
TSLA   182.92 (+0.03%)
NVDA   158.20 (-2.77%)
NIO   10.12 (-0.49%)
BABA   75.80 (+0.40%)
AMD   73.12 (-2.69%)
T   18.79 (-1.73%)
MU   55.74 (-4.57%)
CGC   3.41 (-6.83%)
F   13.73 (-2.49%)
GE   85.49 (-3.01%)
DIS   95.70 (-3.21%)
AMC   7.36 (-2.00%)
PYPL   79.88 (-0.25%)
PFE   49.58 (+0.75%)
NFLX   281.33 (-1.47%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.87 (-1.41%)
AAPL   144.52 (-2.42%)
MSFT   241.12 (-2.57%)
META   108.74 (-2.40%)
GOOGL   96.12 (-1.37%)
AMZN   94.11 (+0.75%)
TSLA   182.92 (+0.03%)
NVDA   158.20 (-2.77%)
NIO   10.12 (-0.49%)
BABA   75.80 (+0.40%)
AMD   73.12 (-2.69%)
T   18.79 (-1.73%)
MU   55.74 (-4.57%)
CGC   3.41 (-6.83%)
F   13.73 (-2.49%)
GE   85.49 (-3.01%)
DIS   95.70 (-3.21%)
AMC   7.36 (-2.00%)
PYPL   79.88 (-0.25%)
PFE   49.58 (+0.75%)
NFLX   281.33 (-1.47%)
NASDAQ:CYTH

Cyclo Therapeutics - CYTH Stock Forecast, Price & News

$1.47
+0.09 (+6.52%)
(As of 11/28/2022 03:59 PM ET)
Add
Compare
Today's Range
$1.42
$1.47
50-Day Range
$0.95
$2.13
52-Week Range
$0.91
$5.48
Volume
402 shs
Average Volume
41,854 shs
Market Capitalization
$12.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CYTH stock logo

About Cyclo Therapeutics (NASDAQ:CYTH) Stock

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

Receive CYTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYTH Stock News Headlines

Cyclo Therapeutics Provides Business Update
Cyclo Therapeutics, Inc. Misses Q2 EPS by 7c
See More Headlines
Receive CYTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYTH Company Calendar

Last Earnings
11/14/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/13/2023

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTH
Employees
9
Year Founded
N/A

Profitability

Net Income
$-14,290,000.00
Net Margins
-747.63%
Pretax Margin
-747.69%

Debt

Sales & Book Value

Annual Sales
$1.59 million
Book Value
$2.43 per share

Miscellaneous

Free Float
7,465,000
Market Cap
$12.47 million
Optionable
Not Optionable
Beta
-0.50

Key Executives

  • Mr. N. Scott FineMr. N. Scott Fine (Age 65)
    CEO & Director
    Comp: $707.05k
  • Mr. C. E Strattan (Age 76)
    Founder & Director
    Comp: $14.67k
  • Mr. Michael Eric Lisjak (Age 49)
    Chief Regulatory Officer & Sr. VP of Bus. Devel.
    Comp: $446.44k
  • Mr. Joshua M. FineMr. Joshua M. Fine (Age 40)
    CFO & Sec.
  • Dr. Jeffrey L. Tate Ph.D. (Age 64)
    COO, Chief Quality Officer & Director
  • Mr. George L. Fails (Age 77)
    Exec. VP and Operations Mang.
  • Ms. Lori McKenna Gorski
    Global Head of Patient Advocacy
  • Dr. Lise Lund Kjems M.D. (Age 58)
    Ph.D., Chief Medical Officer













CYTH Stock - Frequently Asked Questions

How have CYTH shares performed in 2022?

Cyclo Therapeutics' stock was trading at $3.73 at the beginning of 2022. Since then, CYTH stock has decreased by 63.0% and is now trading at $1.38.
View the best growth stocks for 2022 here
.

When is Cyclo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our CYTH earnings forecast
.

How were Cyclo Therapeutics' earnings last quarter?

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) posted its quarterly earnings data on Sunday, November, 14th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.07. The company earned $0.40 million during the quarter. Cyclo Therapeutics had a negative trailing twelve-month return on equity of 120.38% and a negative net margin of 747.63%.

What is Cyclo Therapeutics' stock symbol?

Cyclo Therapeutics trades on the NASDAQ under the ticker symbol "CYTH."

Who are Cyclo Therapeutics' major shareholders?

Cyclo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.57%). Insiders that own company stock include Francis Patrick Ostronic, Jeffrey Tate, Joshua M Fine, Markus Sieger, N Scott Fine and Sharon Hemond Hrynkow.
View institutional ownership trends
.

How do I buy shares of Cyclo Therapeutics?

Shares of CYTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclo Therapeutics' stock price today?

One share of CYTH stock can currently be purchased for approximately $1.38.

How much money does Cyclo Therapeutics make?

Cyclo Therapeutics (NASDAQ:CYTH) has a market capitalization of $11.71 million and generates $1.59 million in revenue each year. The company earns $-14,290,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis.

How can I contact Cyclo Therapeutics?

Cyclo Therapeutics' mailing address is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. The official website for the company is www.ctd-holdings.com. The company can be reached via phone at (386) 418-8060, via email at ir@probankfl.com, or via fax at 321-244-8351.

This page (NASDAQ:CYTH) was last updated on 11/28/2022 by MarketBeat.com Staff